S. V. Lapekin

S. V. Lapekin

Auto-generated profile, based on publicly available information

S. V. Lapekin

Pavlov University

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 April 2021 in Terapevticheskii arkhiv
Verified
Journal Article
Open access
PDF file
AGA Y Gudkova
A Y Gudkova
SLS V Lapekin
S V Lapekin
TBT G Bezhanishvili
T G Bezhanishvili
MTM A Trukshina
M A Trukshina
VDV G Davydova
V G Davydova
ESE V Shlyakhto
E V Shlyakhto
There are presented the literature data and a description of the clinical course of the disease in isolated/predominant cardiac amyloidosis. Amyloid cardiomyopathy is the most common phenocopy of hypertrophic cardiomyopathy. The modern possibilities of non-invasive diagnostics using osteoscintigraphy for the differential diagnosis between amyloid cardiomyopathy caused by AL- and transthyretin amyloidosis are described in detail.

22 January 2019 in Russian Journal of Pediatric Hematology and Oncology
Verified
Journal Article
Open access
PDF file
IKI. V. Kazantsev
I. V. Kazantsev
AGA. G. Gevorgyan
A. G. Gevorgyan
TYT. V. Yukhta
T. V. Yukhta
PTP. S. Tolkunova
P. S. Tolkunova
AKAndrey Kozlov
Andrey Kozlov
BAB. V. Afanasyev
B. V. Afanasyev
Introduction.Neuroblastoma (NB) is the most common extracranial pediatric solid tumor. The high-risk group patients are characterized by adverse prognosis and require intensive complex therapy including high-dose chemotherapy (HDCT) with hematopoietic stem cell transplantation (auto-HSCT). The current study presents a single center experience of HSCT with auto-HSCT for high-risk NB performed in Raisa Gorbacheva Memorial Research Institute of Children Oncology, Hematology and Transplantation, First Pavlov State Medical University of St. Petersburg, Ministry of Health of Russia.Patients and methods.A cohort of 72 consecutive high-risk NB patients was included in the study. Among them 69 patients received Bu-Mel conditioning regimen (busulfan 16 mg/kg, melphalan 140 mg/m2 ), in 3 patients the 5D/5D regimen was used (carboplatin 1000 mg/m2 , irinotecan 150 mg/m2 , temozolomide 750 mg/m2 , etoposide 400 mg/m2 , cyclophosphamide 140 mg/kg). In most cases the autologous hematopoietic stem cells source was bone marrow (BM) (n = 59; 82 %), peripheral blood stem cells (PBSC) (n = 11; 15 %), or BM and PBSC (n = 2; 3 %). In 52/66 (79 %) patients with initial bone marrow involvement the potential transplant contamination was assessed by flow cytometry.Results.The 2-year and 5-year overall (OS) and event-free (EFS) survival was 61 % and 48 %, 41 % and 35 % accordingly. The main adverse factors for OS and EFS were age of more than 18 months at diagnosis, combined bone marrow and bones involvement, MYCN amplification, initial neuron-specific enolase level of more than 100 ng/ml, primary resistance or relapse, and metaiodobenzylguanidinepositive lesions persistence prior to or after HSCT with auto-HSCT.Conclusions.The results achieved are comparable to those described for similar cohorts. Some patient subgroups are unlikely to achieve response after HSCT with auto-HSCT. Therefore, additional stratification methods and treatment modalities are needed.Conflict of interest. The authors declare no conflict of interest.Funding. The study was performed without external funding.

19 August 2024 in New St. Petersburg Medical Records
Verified
Journal Article
Open access
PDF file
MLM. L. Ligidov
M. L. Ligidov
AKA. N. Krutikov
A. N. Krutikov
APA. А. Poliakova
A. А. Poliakova
VAV. V. Ageeva
V. V. Ageeva
SLS. V. Lapekin
S. V. Lapekin
AGA. Ya. Gudkova
A. Ya. Gudkova
Cardiac age-related transthyretin amyloidosis is an underdiagnosed reason of heart failure with preserved ejection fraction, the most frequent form of heart failure. We present a clinical case of detection of transthyretin amyloidosis of the heart at stage I-II of the disease based on biomarkers, which made it possible to send the patient to a third-level hospital and achieve the maximum possible compensation for the disease. Based on this case report, we review modern algorithms allowing to suspect and make the diagnosis, from performing routine tests like ECG and echocardiography to more sophisticated instruments like 2D strain-echocardiography, radiology and endomyocardial biopsy. Also staging systems using biomarkers for cardiac transthyretin amyloidosis are discussed. We consider possible paths to early diagnosis of this disease and nuances of medical therapy.

25 July 2013
Verified
Journal Article
Closed access
NMN V Maĭorov
N V Maĭorov
VDV V Davydenko
V V Davydenko
VAV I Amosov
V I Amosov
SLS V Lapekin
S V Lapekin
ALA P Litvinov
A P Litvinov